Publications by authors named "J E Shipley"

We profiled a large heterogenous cohort of matched diagnostic-relapse tumour tissue and paired plasma-derived cell free DNA (cfDNA) from patients with relapsed and progressive solid tumours of childhood. Tissue and cfDNA sequencing results were concordant, with a wider spectrum of mutant alleles and higher degree of intra-tumour heterogeneity captured by the latter, if sufficient circulating tumour-derived DNA (ctDNA) was present. Serial tumour sequencing identified putative drivers of relapse, with alterations in epigenetic drivers being a common feature.

View Article and Find Full Text PDF

Background: Patients with PAX3/7-FOXO1 fusion-negative rhabdomyosarcomas (fnRMS) harbouring the rare L122R MYOD1 mutation have significantly poorer prognosis than other fnRMS. We undertook a detailed clinicopathological evaluation of a cohort of patients with MYOD1 mutated fnRMS in order to improve risk stratification and treatment options.

Procedure: Histological, mutational and clinical data from a cohort of patients with MYOD1 mutant RMS treated in Europe were analysed.

View Article and Find Full Text PDF

Human land-use intensification threatens arthropod (for example, insect and spider) biodiversity across aquatic and terrestrial ecosystems. Insects and spiders play critical roles in ecosystems by accumulating and synthesizing organic nutrients such as polyunsaturated fatty acids (PUFAs). However, links between biodiversity and nutrient content of insect and spider communities have yet to be quantified.

View Article and Find Full Text PDF
Article Synopsis
  • Desmoplastic small round cell tumor (DSRCT) is an aggressive form of cancer linked to a specific genetic factor called EWS-WT1, and treatment options have not improved significantly in over 20 years.
  • Researchers conducted a comprehensive drug sensitivity test on DSRCT cells and found that they respond well to PARP and ATR inhibitors, both alone and in combination, showcasing these treatments across various models.
  • The study reveals that the combination of these inhibitors causes significant DNA damage and activates immune responses, suggesting that targeting EWS-WT1 could be an effective strategy in treating DSRCT.
View Article and Find Full Text PDF